Cancer-targeted photoimmunotherapy induces antitumor immunity and can be augmented by anti-PD-1 therapy for durable anticancer responses in an immunologically active murine tumor model

• Published in: Cancer Immunology, Immunotherapy Immunotherapy, 2023-01, Vol.72 (1), p.151-168
• Main Authors: Hsu, Michelle A., Okamura, Stephanie M., De Magalhaes Filho, C. Daniel, Bergeron, Daniele M., Rodriguez, Ahiram, West, Melissa, Yadav, Deepak, Heim, Roger, Fong, Jerry J., Garcia-Guzman, Miguel
• Format: Article
• Language: English
• Subjects: Animal models; Animals; Antitumor activity; Cancer; Cancer Research; Cell death; Cell Line, Tumor; Cell membranes; Dendritic cells; Disease Models, Animal; Dyes; Humans; Immunity; Immunogenicity; Immunological memory; Immunology; Immunotherapy; Immunotherapy - methods; Inflammation; Lymphocytes; Lymphocytes T; Medicine; Medicine & Public Health; Memory cells; Mice; Neoplasms - therapy; Oncology; Original; Original Article; PD-1 protein; Phototherapy - methods; Solid tumors; Tumor cells; Tumor Microenvironment; Tumors
• ISSN: 0340-7004; 1432-0851
• DOI: 10.1007/s00262-022-03239-9

The complex immunosuppressive nature of solid tumor microenvironments poses a significant challenge to generating efficacious and durable anticancer responses. Photoimmunotherapy is a cancer treatment strategy by which an antibody is conjugated with a non-toxic light-activatable dye. Following administration of the conjugate and binding to the target tumor, subsequent local laser illumination activates the dye, resulting in highly specific target cell membrane disruption. Here we demonstrate that photoimmunotherapy treatment elicited tumor necrosis, thus inducing immunogenic cell death characterized by the release of damage-associated molecular patterns (DAMPs). Photoimmunotherapy-killed tumor cells activated dendritic cells (DC), leading to the production of proinflammatory cytokines, T cell stimulation, priming antigen-specific T cells, and durable memory T cell responses, which led complete responder mice to effectively reject new tumors upon rechallenge. PD-1 blockade in combination with photoimmunotherapy enhanced overall anticancer efficacy, including against anti-PD-1-resistant tumors. The combination treatment also elicited abscopal anticancer activity, as observed by reduction of distal, non-illuminated tumors, further demonstrating the ability of photoimmunotherapy to harness local and peripheral T cell responses. With this work we therefore delineate the immune mechanisms of action for photoimmunotherapy and demonstrate the potential for cancer-targeted photoimmunotherapy to be combined with other immunotherapy approaches for augmented, durable anticancer efficacy. Moreover, we demonstrate responses utilizing various immunocompetent mouse models, as well as in vitro data from human cells, suggesting broad translational potential.